Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Articles online first > Minerva Cardioangiologica 2020 Jul 08

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Cardioangiologica 2020 Jul 08

DOI: 10.23736/S0026-4725.20.05188-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Latest generation stents: is it time to revive the bioresorbable scaffold?

Andrea BUONO 1 , Alfonso IELASI 1, Antonio COLOMBO 2

1 Interventional and Clinical Cardiology Unit, S. Ambrogio Cardio-Thoracic Center, Milan, Italy; 2 GVM Care and Research, Maria Cecilia Hospital, Cotignola, Ravenna, Italy


PDF


Bioresorbable scaffolds (BRS) have been introduced in the last decade in percutaneous coronary interventions. Despite several advantages being postulated, the negative results from the mid-term follow-up of the Absorb trials have tempered enthusiasm for these innovative devices. The Absorb scaffold was associated with higher rates of target-lesion failure and scaffold thrombosis when compared to current metallic stents, and for this reason was withdrawn from the market. This failure has to be considered multifactorial, involving technical and technological aspects. Continuous engineering refinements in BRS technology, means newer-generation devices are available in clinical practice, and several more are under preclinical and clinical assessment. Thinner and smaller struts, associated with a faster resorption and re-endothelialization process, are at the basis of promising preclinical results for new BRS. In this review we summarise the Absorb scaffold experience and focus on the latest evidence concerning emerging new BRS, to explore if a “BRS revival” is conceivable.


KEY WORDS: Bioresobable scaffold; Percutaneous coronary intervention; Coronary stent; Coronary artery disease

inizio pagina